OptiBiotix Health plc
("OptiBiotix" or the
"Company")
Presentation at ProBiota
2024
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing
compounds to
tackle obesity, high cholesterol and diabetes, announces it will be presenting research and
meeting potential partners at ProBiota 2024 between 7-9
February 2024, in Milan.
ProBiota is the leading annual
event for the global prebiotic, probiotic
and the microbiome focused food and pharma industries. The
conference is world renowned for scientists and industry leaders
who are seeking to translate the latest science into new products
in the supplements and ingredients market.
The Company will be
presenting on novel methods to design a range of
prebiotic approaches which stimulate the growth of probiotics
of commercial interest. These can be used as excipients in
probiotic capsules, tablets, and sachets to selectively support the
growth of the probiotic and enhance its health benefit. These
synbiotics represent an area of growing market interest as a means
to bring innovation and differentiation into the probiotic market
with a forecast CAGR of 8.2% between 2022 and 2027
Synbiotic Products Market Size & Share Analysis - Industry
Research Report - Growth Trends
(mordorintelligence.com)
Commenting, Stephen O'Hara,
CEO of OptiBiotix said: "We were pleased to be presenting our research
on synbiotics at ProBiota. Attending conferences like ProBiota,
which attract scientists from around the world, allow us to present
our work to industry and increases awareness of OptiBiotix and its
products. This often attracts commercial interest in our technology
and helps build the product pipeline in different territories and
with different partners. This increases the scale of the
opportunity, and the potential value of
OptiBiotix."
For further
information, please contact:
|
OptiBiotix
Health plc
|
www.optibiotix.com
|
|
Neil Davidson, Chairman
|
Contact via Walbrook
below
|
|
Stephen O'Hara, Chief Executive
|
|
|
|
|
|
Peterhouse
Capital Limited (Broker)
|
Tel: 020 7220
9797
|
|
Duncan Vasey / Lucy Williams
|
|
|
|
|
|
Walbrook PR
Ltd
|
Mob: 07876 741
001
|
|
Anna Dunphy
|
|
|
|
| |
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI) brings
science to the development of compounds which modify the human
microbiome - the collective genome of the microbes in the body - in
order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D
programme working with leading academics in the development of
microbial strains, compounds, and formulations which are used as
active ingredients and supplements. More than twenty international
food and healthcare supplement companies have signed agreements
with OptiBiotix to incorporate their human microbiome modulators
into a wide range of food products and drinks.
OptiBiotix is also developing its
own range of consumer supplements and health products. The
Company's current areas of focus include obesity, cardiovascular
health, and diabetes.
This communication is a "Reach"
announcement. Reach is a non-regulatory news service. By using this
service an issuer is confirming that the information contained in
this announcement is of a non-regulatory nature. Information
required to be notified under the AIM Rules for Companies, Market
Abuse Regulation or other regulation would be disseminated as an
RNS regulatory announcement and not on RNS Reach.
